A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

NCT06457919 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Tinengotinib
DRUG: abiraterone acetate with prednisone
DRUG: Enzalutamide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]